In the rapidly evolving landscape of healthcare, innovation isn’t just about new treatments — it’s also about how we protect and leverage those innovations to ensure broader access and sustainability. A recent article on Drug Patent Watch highlights a …

In the fiercely competitive world of pharmaceuticals, the race to safeguard market share isn’t just about innovation—it’s about strategic foresight. Yet, many companies find themselves caught off guard by patent expiries, leaving them vulnerable to gen…

In the fiercely competitive world of biologics, securing market exclusivity isn’t just a regulatory milestone—it’s a strategic weapon that can define a company’s trajectory for years to come. Yet, many biotech and pharma companies underestimate the com…

In the high-stakes world of pharmaceutical investing, patents have long been the gold standard for securing exclusive market rights and safeguarding returns. But as the industry matures, a pressing question emerges: Are patents still the ultimate shiel…

In the high-stakes world of pharmaceuticals, the race to bring a generic drug to market is more than just a matter of timing—it’s a complex chess match involving patent strategies, litigation, and market exclusivity. For industry insiders, understandin…

In the high-stakes world of pharmaceutical innovation, complexity isn’t just a challenge—it’s a barrier to growth, profitability, and strategic agility. For companies navigating the labyrinth of generic portfolios, the question isn’t just about expandi…

In today’s rapidly evolving healthcare landscape, the convergence of pharmaceuticals, digital health, and direct-to-patient (DTP) strategies is not just a trend—it’s a seismic shift redefining how we deliver, access, and think about healthcare. This tr…

In the high-stakes world of pharmaceutical innovation, clinical trial results often steal the spotlight. But beneath the surface lies a less obvious, yet equally critical factor shaping the future of drug companies and their valuations: patent portfoli…